Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Clin Lipidol. 2014 Aug 23;9(1):107–112. doi: 10.1016/j.jacl.2014.08.005

Figure 1. LDL-C response to lomitapide over time.

Figure 1

LDL-C values from the time of patient enrollment in the phase 3 study are reported. Arrows indicate key events over the course of treatment. Numbers indicate lomitapide doses. *Prior to this lipid measurement, rosuvastatin and ezetimibe were not taken for 38 days, and lomitapide was not taken for 5 days for non-study-related reasons.